VIVEO (VVEO3) Main Indicators
Basic Data - VVEO3
| Company | VIVEO |
| Corporate Name | CM HOSPITALAR S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Distribuição e comércio atacadista de produtos para saúde. incluindo medicamentos. produtos médico-hospitalares e laboratoriais; vacinas para uso humano; dietas e leites nutricionais; cosméticos. |
| Share | VVEO3 |
| Quote Date | 04/01/2025 |
| Share Type | ON |
| Last Closing | R$ 1.40 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 2.19 M |
| Last Statement | DFP - 12/31/2024 |
| Sector | Saúde |
| Subsector | Comércio e Distribuição |
| Segment | Medicamentos e Outros Produtos |
| Participation Indexes | IBRA, ICON, IGC, IGCT, IGNM, ITAG, SMLL |
| Updated 04/02/2025 | |
Relative Prices - VVEO3
| Price/Earnings | -0.32 |
| Price/SBV | 0.23 |
| Price/Net Sales | 0.04 |
| Price/CFO | 13.23 |
| Price/FCF | -9.52 |
| Price/Total Assets | 0.05 |
| Price/EBIT | -0.52 |
| Price/Working Capital | 0.19 |
| Price/NCAV | -0.09 |
| EV/EBIT | -4.38 |
| EV/EBITDA | -6.85 |
| EV/Net Sales | 0.33 |
| EV/CFO | 110.71 |
| EV/FCF | -79.64 |
| EV/Total Assets | 0.40 |
| Company Market Cap | R$ 451.95 M |
| Enterprise Value | R$ 3.78 B |
| Current Financial Statement Date | 12/31/2024 |
| Current Share Price | R$ 1.40 |
| Share Price Date | 04/01/2025 |
| Dividend Yield | 9.75% |
| Updated 04/02/2025 | |
Income Statement - VVEO3
| Net Revenue | R$ 11.58 B |
| Gross Result | R$ 1.31 B |
| EBIT | - R$ 862.99 M |
| Depreciation and Amortization | - R$ 311.13 M |
| EBITDA | - R$ 551.86 M |
| Net Profit | - R$ 1.42 B |
| Net Profit/Share | - R$ 4.38 |
| Updated 03/27/2025 | |
| Net Revenue | R$ 2.92 B |
| Gross Result | R$ 117.66 M |
| EBIT | - R$ 786.38 M |
| Depreciation and Amortization | - R$ 80.63 M |
| EBITDA | - R$ 705.75 M |
| Net Profit | - R$ 1.09 B |
| Profit/Share | - R$ 3.39 |
| Updated 03/27/2025 | |
Price and Volume Behavior - VVEO3
| Lowest Price 52 weeks | R$ 1.28 |
| Highest Price 52 weeks | R$ 6.96 |
| Variation 2025 | -30.35% |
| Variation 1 year | -77.90% |
| Variation 2 years(total) | -90.79% |
| Variation 2 years(yearly) | -69.56% |
| Variation 3 years(total) | -91.23% |
| Variation 3 years(yearly) | -55.53% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 3.07 M |
| Updated 04/02/2025 | |
Returns and Margins - VVEO3
| Return on Initial Tangible Capital | -12.90% |
| Return on Initial Invested Capital | -9.42% |
| Pre-Tax Return on Initial Tangible Capital | -19.55% |
| Pre-Tax Return on Initial Invested Capital | -14.28% |
| Return on Initial Shareholder´s Equity | -43.03% |
| Return on Initial Asset | -13.90% |
| Gross Margin | 11.27% |
| Net Margin | -12.22% |
| EBIT Margin | -7.45% |
| EBITDA Margin | -4.76% |
| Initial Asset Turnover | 1.14 |
| Financial Leverage | 4.95 |
| Liabilities/Net Worth | 3.95 |
| Net Debt/EBITDA | -6.03 |
| Updated 03/27/2025 | |
Balance Sheet - VVEO3
| Cash and Cash Equivalents | R$ 543.67 M |
| Total Assets | R$ 9.54 B |
| Short-Term Debt | R$ 402.75 M |
| Long-Term Debt | R$ 3.47 B |
| Gross Debt | R$ 3.87 B |
| Net Debt | R$ 3.33 B |
| Shareholder´s Equity | R$ 1.93 B |
| Share Book Value | R$ 5.97 |
| Common Shares | 322,820,608 |
| Preferred Shares | 0 |
| Total | 322,820,608 |
| Common Shares in Treasury | 7,012,300 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 7,012,300 |
| Common Shares (Except Treasury) | 315,808,308 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 315,808,308 |
| Updated 03/27/2025 | |
Cash Flow - VVEO3
| Operating Cash Flow | R$ 34.15 M |
| Cash Flow from Investments | - R$ 272.79 M |
| Financing Cash Flow | R$ 309.61 M |
| Increase (Reduction) in Cash and Equivalents | R$ 70.96 M |
| Updated 03/27/2025 | |
| Operating Cash Flow | - R$ 513.01 M |
| Cash Flow from Investments | R$ 134.19 M |
| Financing Cash Flow | - R$ 207.57 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 586.40 M |
| Updated 03/27/2025 | |
Experimental - VVEO3
| CAPEX 3 months | - R$ 32.00 M |
| Free Cash Flow 3 months | - R$ 545.01 M |
| CAPEX 12 months | - R$ 81.62 M |
| Free Cash Flow 12 months | - R$ 47.47 M |
| Updated 03/27/2025 | |